|
1. Balthasar J and Fung
HL, Utilization of antidrug antibody fragments for the
optimization of intraperitoneal drug therapy: studies using
digoxin as a model drug. J Pharm Exp Ther 268(2):
734-9, 1994.
2. Balthasar JP and Fung
HL, High-affinity rabbit antibodies directed against
methotrexate: production, purification, characterization, and
pharmacokinetics in the rat. Journal of Pharmaceutical
Sciences 84(1): 2-6, 1995.
3. Balthasar JP and Fung
HL, Pharmacokinetic and pharmacodynamic optimization of
intraperitoneal chemotherapy. Life Sciences 58(7):
535-543, 1996.
4. Balthasar JP Fung HL,
Inverse targeting of peritoneal tumors: selective alteration of
the disposition of methotrexate through the use of anti-methotrexate
antibodies and antibody fragments. J Pharm Sci 85(10):
1035-43, 1996.
5. Bauer JA, Balthasar
JP and Fung H-L, Application of pharmacodynamic modeling for
designing time-variant dosing regimens to overcome nitroglycerin
tolerance in experimental heart failure. Pharm Res 14(9):
1140-45, 1997.
6. Hansen RJ and
Balthasar JP, An ELISA for quantification of murine IgG in rat
plasma: application to the pharmacokinetic characterization of
AP-3, a murine anti-glycoprotein IIIa monoclonal antibody, in
the rat. Journal of Pharmaceutical and Biomedical Analysis
21: 1011-1016, 1999.
7. Lobo ED and Balthasar
JP, Highly sensitive high performance liquid chromatographic
assay for methotrexate in the presence and absence of anti-methotrexate
antibody fragments in rat mouse and plasma. Journal of
Chromatography, B. 736: 191-199, 1999.
8. Balthasar JP,
Vinorelbine tartrate and heparin sodium incompatibility.
American Journal of Heath-System Pharmacy 56(Sept 15):
1891, 1999.
9. Balthasar JP,
Bioequivalence and bioequivalency testing. American Journal
of Pharmaceutical Education 63(2): 194-198,
1999.
10. Hansen RJ and
Balthasar JP, Pharmacokinetics, pharmacodynamics, and platelet
binding of 7E3, a murine anti-glycoprotein IIb/IIIa monoclonal
antibody in the rat. Journal of Pharmacology and Experimental
Therapeutics 298(1): 165-171, 2001.
11. Hansen RJ and
Balthasar JP, Effects of intravenous immunoglobulin on platelet
count and antiplatelet antibody disposition in a rat model of
immune thrombocytopenia. Blood 100(6):
2087-2093, 2002.
12. Hansen RJ and
Balthasar JP, Intravenous immunoglobulin mediates an increase in
anti-platelet antibody clearance via the FcRn receptor.
Thrombosis and Haemostasis 88(6): 898-899, 2002.
13. Lobo ED and Balthasar
JP, Pharmacodynamic modeling of chemotherapeutic effects:
Application of a transit-compartment model to characterize
methotrexate effects in vitro.
AAPS PharmSci
, article 42 http://www.aapspharmsci.org/scientific journals/pharmsci/journal/ps040442.htm,
2002.
14. Hansen RJ and
Balthasar JP, IVIG effects on antiplatelet antibody levels and
on platelet opsonization in ITP. Blood 101(4):
1659, 2003.
15. Hansen RJ and
Balthasar JP, PK/PD modeling of the effects of intravenous
immunoglobulin on the disposition of anti-platelet antibodies in
a rat model of immune thrombocytopenia. Journal of
Pharmaceutical Sciences, 92(6): 1206-1215, 2003.
16. Lobo ED and Balthasar
JP, Pharmacokinetic-pharmacodynamic modeling of
methotrexate-induced toxicity in mice. Journal of
Pharmaceutical Sciences , 92(8): 1654-1664, 2003.
17. Lobo ED, Soda DM and
Balthasar JP, Application of pharmacokinetic - pharmacodynamic
modeling to predict the kinetic and dynamic effects of anti-methotrexate
antibodies in mice. Journal of Pharmaceutical Sciences ,
92(8): 1665-1676, 2003.
18. Wang EQ, Balthasar JP
and Fung HL, Pharmacodynamic modeling of in vivo nitroglycerin (NTG)
tolerance in conscious rats: Effects of dose and dosage regimen.
Pharmaceutical Research, 21(1): 114-120, 2004.
19. Hansen RJ and
Balthasar JP, Mechanisms of IVIG action in ITP, Clinical
Laboratory, 50(3/4): 133-140, 2004.
20. Lobo ED, Hansen RJ,
Balthasar JP, Antibody pharmacokinetics and pharmacodynamics.
Journal of Pharmaceutical Sciences, 93(11):
2645-2668), 2004.
21. Hansen RJ and
Balthasar JP, IVIG effects on autoantibody elimination,
Allergy, 59(10): 1124, 2004.
22. Tayab ZR and
Balthasar JP, Development and validation of enzyme-linked
immunosorbent assays for quantification of anti-methotrexate IgG
and Fab in mouse and rat plasma. Journal of Immunoassay and
Immunochemistry, 25(4): 333-324, 2004.
23. Chen J and Balthasar
JP, High-performance liquid chromatographic assay for the
determination of total and free
topotecan in the presence
and absence of anti-topotecan antibodies in mouse plasma. J
Chrom B Analyt Technol
Biomed Life Sci,
816(1-2): 183-192, 2005.
24. Getman K and
Balthasar JP, Pharmacokinetic effects of 4C9, an anti-FcRn
antibody, in rats: Implications for the use of
FcRn inhibitors for the
treatment of humoral autoimmune and alloimmune conditions. J
Pharm Sci, 94(4): 718-729,
2005.
25. Lobo ED and Balthasar
JP, Application of anti-methotrexate Fab fragments for the
optimization of intraperitoneal
methotrexate therapy in a
murine model of peritoneal cancer. J Pharm Sci
94:1957-64,2005.
26. Emregul E, David A,
Balthasar JP and Yang VC, A GPIIb/IIIa bioreactor for specific
treatment of immune
thrombocytopenic purpura,
an autoimmune disease. Preparation, in vitro characterization,
and preliminary proof-of-
concept animal studies.
J Biomed Mater Res A 75(3): 648-55, 2005.
27. Deng R and Balthasar
JP, Investigation of antibody-coated liposomes as a new
treatment for immune
thrombocytopenia. Int
J Pharm 304(1-2): 51-62, 2005.
28. Wang T, Yang Z,
Emregul E, David A, Balthasar JP, Liang J and Yang VC,
Strategies for improving the functionality
of an affinity
bioreactor. Int J Pharm, 2005.
29. Jin F and Balthasar
JP, Mechanisms of intravenous immunoglobulin in immune
thrombocytopenic purpura. Human
Immunology,
66: 403-410, 2005.
30. Jin F, Tayab ZR and
Balthasar JP, Pharmacokinetic and pharmacodynamic effects of
high-dose monoclonal antibody
therapy in a rat model of
immune thrombocytopenia. AAPS J. 2006 Jan
13;7(4):E895-902.
31. Deng R and Balthasar
JP, Pharmacokinetic/pharmacodynamic modeling of IVIG effects in
a murine model of immune
thrombocytopenia. J
Pharm Sci, 96(6):1625-1637, 2007.
32. Deng R. and Balthasar
JP, Comparison of the effects of antibody-coated liposomes, IVIG
and anti-RBC
immunotherapy in a murine
model of passive chronic immune thrombocytopenia. Blood,
109(6):2470-2476, 2007.
33. Shin BS, Choi JW,
Balthasar JP, Hong DK, Kim JJ, Yoo SD, Determination of
roxatidine in human plasma by liquid
chromatography/electrospray
mass spectromety and application to a clinical pharmacokinetic
study, Rapid Commun
Mass Spectrom.,
21(3):329-35, 2007.
34. Chen J, Lu Q, and
Balthasar JP, Mathematical modeling of topotecan
pharmacokinetics and toxicodynamics in mice. Journal of
Pharmacokinetics and Pharmacodynamics, 34(6):829-847., 2007.
35. Garg A and Balthasar
JP, Application of a physiologically-based pharmacokinetic model
to predict IgG tissue kinetics in
wild-type and FcRn-knockout
mice. J Pharmacokinetics and Pharmacodynamics,
34(5):711-723, 2007.
|
